Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBLUMEN: Obinutuzumab for systemic lupus erythematosus pure membranous nephropathy
2024-519985-35-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of obinutuzumab in lupus nephritis (LN) and systemic lupus erythematosus (SLE), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Complete renal response at week 52 without intercurrent event. Planned start Jul 2026; status: authorised.
02
Drugs
obinutuzumab
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2024-519985-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519985-35-00.